Catheter Precision Announces September 10th, 2025 Record Date for October 10th, 2025 Special Meeting of Stockholders
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology products, has set September 10th, 2025 as the record date for its upcoming Special Meeting of Stockholders scheduled for October 10th, 2025.
During the meeting, stockholders will vote on two key proposals: increasing the company's authorized shares of common stock and appointing WithumSmith+Brown, PC as the independent auditor for fiscal year 2026. The preliminary proxy statement detailing these matters is expected to be filed with the SEC on September 4th, 2025.
Catheter Precision (NYSE:VTAK), azienda di dispositivi medici specializzata in prodotti per l'elettrofisiologia cardiaca, ha fissato il 10 settembre 2025 come data di registrazione per la prossima Assemblea Straordinaria degli Azionisti, in programma per il 10 ottobre 2025.
Durante l'assemblea gli azionisti voteranno su due proposte principali: l'aumento delle azioni ordinarie autorizzate della società e la nomina di WithumSmith+Brown, PC come revisore indipendente per l'esercizio 2026. Il prospetto preliminare che illustra tali questioni è previsto in deposito presso la SEC il 4 settembre 2025.
Catheter Precision (NYSE:VTAK), una empresa de dispositivos médicos especializada en productos de electrofisiología cardiaca, ha establecido el 10 de septiembre de 2025 como fecha de registro para su próxima Junta Extraordinaria de Accionistas, programada para el 10 de octubre de 2025.
En la junta, los accionistas votarán dos propuestas clave: aumentar las acciones ordinarias autorizadas de la compañía y nombrar a WithumSmith+Brown, PC como auditor independiente para el ejercicio fiscal 2026. Se espera que la declaración preliminar del poder con estos asuntos se presente ante la SEC el 4 de septiembre de 2025.
Catheter Precision (NYSE:VTAK)는 심장 전기생리학 제품을 전문으로 하는 의료기기 회사로, 다가오는 임시 주주총회(개최일: 2025년 10월 10일)의 기록 기준일을 2025년 9월 10일로 정했습니다.
총회에서 주주들은 회사의 보통주 발행 한도 증액 및 WithumSmith+Brown, PC를 2026 회계연도 독립 감사인으로 임명하는 두 건의 주요 안건에 대해 표결합니다. 이들 사안이 담긴 예비 위임장(프록시) 성명서는 2025년 9월 4일에 SEC에 제출될 예정입니다.
Catheter Precision (NYSE:VTAK), société de dispositifs médicaux spécialisée dans les produits d'électrophysiologie cardiaque, a fixé le 10 septembre 2025 comme date d'inscription pour sa prochaine Assemblée Générale Extraordinaire des actionnaires, prévue le 10 octobre 2025.
Lors de l'assemblée, les actionnaires voteront sur deux propositions principales : l'augmentation du nombre d'actions ordinaires autorisées de la société et la nomination de WithumSmith+Brown, PC en tant qu'auditeur indépendant pour l'exercice 2026. La déclaration de procuration préliminaire détaillant ces points devrait être déposée auprès de la SEC le 4 septembre 2025.
Catheter Precision (NYSE:VTAK), ein Medizintechnikunternehmen, das sich auf Produkte der kardialen Elektrophysiologie spezialisiert hat, hat den 10. September 2025 als Stichtag für seine bevorstehende außerordentliche Hauptversammlung der Aktionäre festgelegt, die für den 10. Oktober 2025 angesetzt ist.
Auf der Versammlung werden die Aktionäre über zwei zentrale Vorschläge abstimmen: die Erhöhung der genehmigten Stammaktien der Gesellschaft und die Bestellung von WithumSmith+Brown, PC als unabhängige Wirtschaftsprüfer für das Geschäftsjahr 2026. Die vorläufige Proxy-Erklärung zu diesen Punkten soll am 4. September 2025 bei der SEC eingereicht werden.
- None.
- None.
FORT MILL, S.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that September 10th, 2025, is the Record Date for the October 10th Special Meeting of the stockholders. We are seeking stockholder approval to amend our Certificate of Incorporation to increase our authorized shares of common stock, and to appoint WithumSmith+Brown, PC as our independent auditor for our fiscal year 2026. Additional details are available in the preliminary proxy statement anticipated to be filed with the SEC on September 4th, 2025.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding the filing of a preliminary proxy statement and the timing and anticipated business to be conducted our upcoming special meeting. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov. Timing of the meeting, the business to be conducted at the meeting, and the timing of related SEC filings may also be impacted by market developments or changes in business plans.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Important Additional Information and Where to Find It
Catheter Precision, Inc. (the “Company”) plans to file proxy materials with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the solicitation of proxies for the Company’s October 10, 2025 special meeting of stockholders (the “2025 Special Meeting”). Stockholders will be able to obtain, free of charge, copies of the Preliminary and Definitive Proxy Statement, any amendments or supplements thereto and any other documents (including the proxy card) when filed by the Company with the SEC at the SEC’s website (http://www.sec.gov) or at the Company’s website (https://www.catheterprecision.com).
Certain Information Regarding Participants in the Solicitation
The Company, its directors and certain of its executive officers and other employees may be deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from stockholders in connection with the 2025 Special Meeting. Information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement and other materials to be filed with the SEC in connection with the 2025 Special Meeting.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
When is Catheter Precision (VTAK) holding its Special Meeting of Stockholders?
What will stockholders vote on at Catheter Precision's Special Meeting?
Who is the proposed new auditor for Catheter Precision (VTAK)?
When will Catheter Precision file the preliminary proxy statement?
